Clinical Trials
22 trialsNCT02609776 2026-06-05
CHRYSALIS
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05379595 2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05488314 2026-06-05
METalmark
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05498428 2026-06-05
PALOMA-2
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05908734 2026-06-05
PolyDamas
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT06120140 2026-06-05
COCOON
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06385080 2026-06-05
OrigAMI-4
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT06662786 2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06667076 2026-06-05
COPERNICUS
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06750094 2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07227025 2026-06-05
KaRAnaSa
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07276399 2026-06-05
OrigAMI-5
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05663866 2026-06-02
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07586202 2026-05-14
AmiNA
Janssen Research & Development, LLC
Phase 2 Not yet recruiting
NCT04077463 2026-05-08
Chrysalis-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04487080 2026-05-08
MARIPOSA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04538664 2026-05-08
PAPILLON
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04988295 2026-05-08
MARIPOSA-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05388669 2026-05-08
PALOMA-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06816992 2026-04-24
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT06532032 2026-04-13
swalloWTail
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05801029 2026-03-20
OSTARA
AstraZeneca
Phase 2 Active not recruiting